Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

November 1, 2020

Study Completion Date

September 1, 2021

Conditions

Infection, Meningococcal

Interventions

BIOLOGICAL

Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine

0.5mL single intramuscular dose on Day 0

BIOLOGICAL

Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine

0.5mL single intramuscular dose on Day 0

Trial Locations (1)

Seoul National University Hospital, Seoul